3-氯-4-(4-噻唑甲氧基)苯胺 | 833474-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-氯-4-(4-噻唑甲氧基)苯胺
• 英文名称: 3-chloro-4-(thiazol-4-ylmethoxy)aniline
• 英文别名: 3-Chloro-4-[(1,3-thiazol-4-yl)methoxy]aniline；3-chloro-4-(1,3-thiazol-4-ylmethoxy)aniline
• CAS: 833474-42-3
• 化学式: C₁₀H₉ClN₂OS
• 分子量: 240.713
• InChiKey: IGWUQCZRXYYZON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  76.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氯-4-(4-噻唑甲氧基)苯胺 、 1-(4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidin-1-yl)prop-2-en-1-one 在 对甲苯磺酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以45.2 %的产率得到1-[4-[4-[3-chloro-4-(thiazol-4-ylmethoxy)anilino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1-piperidyl]prop-2-en-1-one
  参考文献：
  名称：

  HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES

  摘要：

  Disclosed are heteroaryl compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.

  公开号：

  US20240059698A1
• 作为产物：
  描述：

  4-[(2-chloro-4-nitro-phenoxy) methyl] thiazole 以95.59 %的产率得到3-氯-4-(4-噻唑甲氧基)苯胺
  参考文献：
  名称：

  HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES

  摘要：

  Disclosed are heteroaryl compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.

  公开号：

  US20240059698A1

文献信息

• Novel Heterocycles
  申请人：Zhang Chengzhi

  公开号：US20080132497A1

  公开（公告）日：2008-06-05

  This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly hyperproliferative diseases such as cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly hyperproliferative diseases such as cancer.

  本发明涉及新型化合物及其制备方法，治疗疾病的方法，特别是治疗高增殖性疾病，如癌症的方法，包括给予所述化合物，并制备用于治疗或预防疾病的药物组合物的方法，特别是治疗高增殖性疾病，如癌症的药物组合物。
• NOVEL HETEROCYCLES
  申请人：Zhang Chengzhi

  公开号：US20110172224A1

  公开（公告）日：2011-07-14

  The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.

  本发明涉及公式（I）的新异环化合物，其制备方法以及它们用于制备治疗或预防疾病，特别是过度增殖性疾病的药物的用途。
• Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors
  作者：Alex G. Waterson、Kimberly G. Petrov、Keith R. Hornberger、Robert D. Hubbard、Douglas M. Sammond、Stephon C. Smith、Hamilton D. Dickson、Thomas R. Caferro、Kevin W. Hinkle、Kirk L. Stevens、Scott H. Dickerson、David W. Rusnak、Glenn M. Spehar、Edgar R. Wood、Robert J. Griffin、David E. Uehling

  DOI：10.1016/j.bmcl.2009.01.080

  日期：2009.3

  Aniline 'headgroups' were synthesized and incorporated into an alkynyl thienopyrimidine series of EGFR and ErbB-2 inhibitors. Potent inhibition of enzyme activity and cellular proliferation was observed. In certain instances, protein binding was reduced and oral exposure was found to be somewhat improved relative to compounds containing the reference aniline. (C) 2009 Elsevier Ltd. All rights reserved.
• BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP1802633A1

  公开（公告）日：2007-07-04
• Condensed thienopyrimidine derivatives for the treatment of cancer
  申请人：Bayer Intellectual Property GmbH

  公开号：EP1799653B1

  公开（公告）日：2013-03-20